Clinical Colorectal Cancer, 21(2), 154-166. Elsevier on behalf of the QUALITAS study group 2022, ' Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS) ', Clinical Colorectal Cancer, vol. 21, no. 2, pp. 154-166 . https://doi.org/10.1016/j.clcc.2022.03.002 Clinical colorectal cancer, 21(2), 154-166. Elsevier Clinical Colorectal Cancer, 21(2), 154-166. CIG Media Group, L.P.
European Journal of Cancer, 158, 144-155. Elsevier Limited European Journal of Cancer, 158, 144-155. Pergamon European Journal of Cancer, 158, 144-155. Elsevier Ltd. European Journal of Cancer, 158, pp. 144-155 PLCRC study group 2021, ' Trajectories of health-related quality of life and psychological distress in patients with colorectal cancer : A population-based study ', European Journal of Cancer, vol. 158, pp. 144-155 . https://doi.org/10.1016/j.ejca.2021.08.050 European Journal of Cancer, 158, 144-155
Werter, I M, Huijts, C M, Lougheed, S M, Hamberg, P, Polee, M B, Tascilar, M, Los, M, Haanen, J B A G, Helgason, H H, Verheul, H M, de Gruijl, T D, van der Vliet, H J & Dutch WIN-O Consortium 2019, ' Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus ', Cancer Immunology, Immunotherapy, vol. 68, no. 5, pp. 787-798 . https://doi.org/10.1007/s00262-019-02313-z Cancer Immunology, Immunotherapy, 68(5), 787-798. Springer Science and Business Media Deutschland GmbH Cancer Immunology Immunotherapy, 68, 5, pp. 787-798 Cancer immunology, immunotherapy, 68(5), 787-798. Springer Science and Business Media Deutschland GmbH Cancer Immunology Immunotherapy, 68, 787-798